Single‐dose NEPA versus an aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy

Single‐dose NEPA versus an aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy

Abstract Introduction Non‐inferiority of NEPA (fixed combination of NK1 receptor antagonist (RA), netupitant, and 5‐HT3RA, palonosetron) versus an aprepitant regimen was previously shown in a pragmatic study in patients receiving anthracycline cyclophosphamide (AC) and non‐AC moderately emetogenic c...

Full description

Bibliographic Details
Main Authors: Laurent Zelek, Rudolph Navari, Matti Aapro, Florian Scotté
Format: Article
Language:English
Published: Wiley 2023-08-01
Series:Cancer Medicine
Subjects:
aprepitant
CINV
NEPA
netupitant
palonosetron
Online Access:https://doi.org/10.1002/cam4.6121

Internet

https://doi.org/10.1002/cam4.6121

Similar Items